United States: SEC Reaches Settlement With Political Intelligence Firm, But Does Not Charge Insider Trading

On November 24, 2015, the Securities and Exchange Commission (the "SEC") announced that political intelligence firm, Marwood Group Research LLC ("Marwood"), agreed to admit wrongdoing and pay a $375,000 penalty for compliance failures, ending one of the SEC's "landmark investigations into the political-intelligence industry."1 As part of the settlement, Marwood also agreed to retain an independent compliance consultant to review and make recommendations regarding Marwood's supervisory, compliance and other policies and procedures as they relate to the obtaining or use of material, nonpublic information ("MNPI"). Marwood, a registered broker-dealer, and state-registered investment adviser, admitted that it failed in 2010 to establish, maintain, and enforce written policies and procedures reasonably designed to prevent the misuse of MNPI consistent with the nature of its business as required by Section 15(g) of the Securities and Exchange Act of 1934 (the "Exchange Act") and Section 204A of the Investment Advisers Act of 1940 (the "Advisers Act").

Marwood provides hedge funds and other clients with regulatory updates and insights into developments and the potential timing of future government actions or rulemaking decisions. During 2010, Marwood sought and received information from government employees concerning pending regulatory or policy issues involving the agencies that employed the government sources. Some of the information, in the context in which it was conveyed, was determined by the SEC to present a substantial risk that it could be MNPI. Marwood conveyed this information through research notes and other written and oral forms of communication to its clients, who the SEC alleged were likely to use such information to inform their trading in relevant securities. Although Marwood's written policies and procedures prohibited the acquisition and dissemination of MNPI and required employees to bring it to the attention of the compliance department if they encountered anything confidential, Marwood's analysts failed to do so.

The SEC's investigation of—and settlement with—Marwood is noteworthy. The SEC has appeared to prioritize its inquiries into political intelligence firms over the past year. Given its interest in these types of cases, it is notable that the SEC charged Marwood with compliance shortcomings, but failed to charge Marwood with violating the insider trading laws. This could reflect the possibility that the SEC was unable to identify a breach of duty by an insider in exchange for a personal benefit (the standard articulated by the Second Circuit in its seminal decision, United States v. Newman2), which has become a recurring obstacle for the government in establishing its insider trading cases. The SEC's settlement and focus on compliance also reflects its commitment to holding compliance programs and compliance officers to a high standard that takes into account a firm's business model in the program's design and implementation.

Relevant Factual Background

Marwood's business is to research and provide reports and updates to subscribing clients interested in market-moving regulatory and legislative events. Marwood's clients were historically comprised predominantly of mutual funds, investment advisers, and hedge funds. Marwood's "research notes" that were distributed to its clients often included previews of anticipated legislative or regulatory developments and analysis of already undertaken government actions, the latter of which may include insights into the implications of the government action.

To enhance Marwood's ability to provide accurate and commercially valuable research opining on future government regulatory events, Marwood encouraged its analysts to maintain contacts and seek information from personnel within the federal government. Marwood also arranged meetings and phone calls with government employees that sometimes could include representatives of Marwood's clients. During these meetings and calls, Marwood employees sought and obtained information from the government employees that it could (and would) use to inform the research which it would in turn share with paying clients.

By 2010, in addition to its written policies and procedures concerning the use and dissemination of MNPI, Marwood's policies and procedures provided for a review process over the preparation and publication of its regulatory and legislative research notes. These policies and procedures required review and approval by a licensed supervisory principal and submission of the reviewed material through the compliance department. If a Marwood employee had any doubt as to whether he or she was in possession of inside information, the employee was required to refrain from communicating it further and to promptly notify Marwood's compliance department. However, as of 2010, Marwood's policies and procedures did not expressly require the compliance department to be advised as to the source of the information included in the research note, or about communications with government sources, if any.

Marwood's compliance deficiencies and its analysts' failure to communicate as required with the compliance department would prove costly for Marwood in two separate instances that year—one involving the Centers for Medicare and Medicaid Services ("CMS"), and the other involving the Food and Drug Administration ("FDA"). CMS is tasked with crafting and enforcing Medicare coverage and reimbursement rates for eligible medical products and services. For certain medical products and services, CMS may make a National Coverage Determination ("NCD") to determine the criteria for coverage of that product or service on a national basis for all Medicare beneficiaries. The process that leads to an NCD is often referred to as a National Coverage Analysis ("NCA"). The goal of an NCA is to determine whether an item or service is "reasonable and necessary" for the diagnosis of a specific illness or injury; because such determination can change Medicare coverage, the announcement of an NCD can be a material event that impacts the market value of the securities of public companies sponsoring the product or service.

On June 30, 2010, CMS opened an NCA to determine whether or not Provenge, an immunotherapy manufactured by Dendreon and approved by the FDA earlier that year, was "reasonable and necessary" for Medicare beneficiaries. Upon this announcement, there was a sharp drop in the price of Dendreon's stock.

While CMS staff were permitted to inform the public on various topics, they were also governed by a confidentiality policy and agency regulations that restricted the information they could disclose. In the summer of 2010, Marwood employed an analyst who was a former CMS employee who had worked in the NCA group. On July 7, 2010, the Marwood analyst was able to obtain "decent color" from a former colleague at CMS as to why an NCA had been issued for Provenge. The CMS employee expressly warned the Marwood analyst of the sensitivity of this information. Based on this information, the Marwood analyst formed an opinion predicting CMS's continued coverage and reimbursement of Provenge's on-label usages; however, this information was never disclosed to Marwood's compliance department, in violation of Marwood's written policies and procedures. On July 8, Marwood published a research note entitled "Provenge NCA Likely to Support On-Label Coverage," which it circulated to hundreds of clients.

Separately in 2010, Marwood had retained a former high-ranking FDA official to consult on and assist with Marwood's analysis of FDA issues, including a pending application for a new diabetes drug called Bydureon. On September 14, 2010, the consultant and certain Marwood employees had a 73-minute phone call during which they discussed the consultant's assessment of Bydureon's new drug application. According to one Marwood employee's notes, the consultant conveyed that certain FDA contacts of his were "concerned about approval" and that there was "a debate between safety and reviewers." The consultant described several specific safety concerns that he believed the FDA was deliberating. This information was never quarantined or brought to the attention of Marwood's compliance department; rather, Marwood began communicating with clients between September 14 and October 19, 2010, informing them of this internal debate at the FDA concerning the safety of Bydureon and of the under-appreciated risk in the market that the new drug application could be denied.

The SEC's Investigation and Findings

The Wall Street Journal reported on October 28, 2014 that the SEC was investigating whether or not officials at CMS may have leaked news relating to Provenge to, among others, Marwood.3 A little more than a year later, on November 24, 2015, the SEC announced that it had instituted and settled an administrative proceeding against Marwood.

The SEC order (the "Order") states that Marwood's analysts used potential MNPI that they had gained from interactions with government contacts in formulating research notes that were distributed to clients. The SEC found that Marwood had no written policy or procedure to reasonably ensure that its chief compliance officer would be provided with sufficient information to assess whether a research note may have been influenced by improperly obtained MNPI or to evaluate independently other Marwood employees' assessments that any information they had received from a government employee was not MNPI. Rather, Marwood's policy principally relied on employees and managers' own assessments of the risk.

Relying on earlier precedents, the SEC posited that Marwood's written policies and procedures "failed to address the substantial risk that its analysts who were in contact with government employees likely to be in possession of potential MNPI, could obtain and disseminate MNPI to Marwood's clients, who were likely to use that information to inform their securities trading."4 Thus, the SEC concluded that Marwood's written policies and procedures "were not reasonably designed to address the risks associated with the nature of its business activities . . . [and that] its policies in this regard were also not reasonably enforced."5

Based on this conduct, the SEC charged Marwood with violating Section 15(g) of the Exchange Act, which requires every registered broker-dealer "to establish, maintain, and enforce written policies and procedures reasonably designed, taking into consideration the nature of such broker's or dealer's business, to prevent the misuse in violation of . . . [the Exchange Act] or the rules or regulations thereunder, of material nonpublic information by such broker or dealer or any person associated with such broker or dealer."6 However, as the SEC noted in the Order, there is "no requirement under Section 15(g) that there be an underlying insider trading violation or any other violation of the Exchange Act or the rules thereunder."7 The SEC also charged Marwood with violating Section 204A of the Advisers Act, which contains the same policy and procedure requirements for investment advisers as required of broker-dealers under Section 15(g) of the Exchange Act.


The SEC's settlement with Marwood is noteworthy in several respects. For one, the SEC's willingness to settle with Marwood without charging insider trading could reflect the increasing difficulty regulatory authorities face when instituting enforcement proceedings in a post-Newman world, where the Second Circuit has held that the government must establish a breach of duty in exchange for a personal benefit, and thus an indication that the SEC was unable to identify a breach in exchange for a personal benefit by the purported government insider. Second, and perhaps of more practical significance, the SEC found a way to charge Marwood through compliance failures. The Order notes that "if the nature of a particular broker-dealer's or investment adviser's business exposes employees to persons in possession of MNPI on a regular basis, a general policy that those employees self-evaluate information they receive is insufficient to comply with Section 15(g) of the Exchange Act and Section 204(A) of the Advisers Act."8 Consequently, registered investment advisers and broker-dealers should review their written policies and procedures and implementation of the same with respect to MNPI that may enter the firm and its relationship to the firm's business operations.


1. Brody Mullins & Aruna Viswanatha, Marwood Group Settles SEC Charges, THE WALL STREET JOURNAL, November 24, 2015, available here.

2. 773 F.3d 438 (2d Cir. 2014).

3. See Brody Mullins, Susan Pulliam & Christopher Weaver, Insider-Trading Probe Focuses on Medicare Agency, THE WALL STREET JOURNAL, October 28, 2014, available here.

4. Order at ¶ 36. The Order is available here.

5. Id.

6. Id. at ¶ 37.

7. Id. at ¶ 37, n.2.

8. Id. at ¶ 35.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.